Research Papers: Immunology:
A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A
Metrics: PDF 1544 views | HTML 3438 views | ?
Tianshu Xu1, Tianlei Ying2, Lili Wang2, Xiaohua Douglas Zhang3, Ying Wang4, Lishan Kang5, Tao Huang5, Liang Cheng5, Liping Wang1 and Qi Zhao3
1 School of Life Science, Jilin University, Changchun, Jilin, China
2 School of Basic Medical Sciences, Fudan University, Shanghai, China
3 Faculty of Health Sciences, University of Macau, Taipa, Macau, China
4 Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau, China
5 Novo Nordisk Research Centre China, Beijing, China
Qi Zhao, email:
Liping Wang, email:
Keywords: bispecific antibody, Fc heterodimerization, TNF-α, IL-17, rheumatoid arthritis, Immunology and Microbiology Section, Immune response, Immunity
Received: April 04, 2017 Accepted: July 12, 2017 Published: August 03, 2017
Anti-tumor necrosis factor (TNF) therapies are successful in the treatment of inflammatory disorders. However, some patients with rheumatoid arthritis (RA) fail to response anti-TNF drugs due to the compensation of other inflammatory signals. In this study, to reduce compensatory responses of interleukin-17A (IL-17A) during TNF-α inhibition, we generated an IgG-like bispecific antibodiy (bsAb) against TNF-α and IL-17A through a combination method of electrostatic Fc pairing and light chain crossover. This bsAb exhibited relatively high stability comparable to natural IgG antibodies, and retained the unaltered affinities to both of two targets. BsAb significantly decreased not only the expression level of neutrophil or Th17 chemokines, but also the secretion of IL-6/IL-8 on fibroblast-like synoviocytes (FLS) from a patient with RA. Meanwhile, TNF-α-mediated cellular cytotoxicity of fibroblasts was neutralized by bsAb. Importantly, we demonstrate that the combined blockade of TNF-α and IL-17A is more efficient than inhibition of either factor alone. Our results suggest the IgG-like anti-TNF-α/IL-17A bispecific molecule overcome the limited therapeutic responses using anti-TNF drugs. It may be a promising therapeutic agent for the treatment of autoimmune diseases.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.